Stem-cell based therapy for kidney repair

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Stem-cell based therapy for kidney repair
Project Number: CORDIS-105515
Project web address: Follow on CORDIS
Organization: Academisch Ziekenhuis Leiden, Netherlands, Leiden
Collaborators: University Of Queensland, AU
King'S College London, GB
Murdoch Children'S Research Institute, AU
Imperial College Of Science, Technology And Medicine, GB
Università Degli Studi Di Firenze, IT
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universiteit Twente, NL
Universiteit Maastricht, NL
Miltenyi Biotec Gmbh, DE
Xpand Biotechnology Bv, NL
Nierstichting Nederland, NL
The Antibody Lab Gmbh, AT
Azienda Ospedaliera Papa Giovanni Xxiii, IT
The Australian Kidney Foundation - Kidney Health Australia, AU
Principal Investigators (PI): Enrico Maggi, IT
Paul Labbett, GB
Ferdinand Damhuis, NL
Maria Grazia Pezzoni, IT
Tatjana Palalic, GB
Ian Harris, AU
Joost De Bruijn, NL
Renate Berger-Mostler, AT
Sabrina Schmitz, DE
Andrej Borejko, NL
Joanna Stoic, AU
Mara Magri, IT
Nicole Donker, AU
Jasper Boomker, NL
AJ Rabelink, NL
Project Description:
Chronic kidney disease (CKD) affects 8% of the European population and ultimately results in renal failure due to progressive fibrosis. CDK carries a high mortality risk and the number of affected people rises, increasing the demand on renal replacement therapies while the number of available donor organs stays stable.The STELLAR consortium proposes to develop an alternative to renal replacement therapy, based on the repair capacity of newly discovered kidney mesenchymal stromal cells (kMSCs). By injecting kMSC into affected kidneys, we expect to stop kidney fibrosis and induce tissue repair, ultimately leading to the restoration of normal kidney function.The STELLAR consortium will• develop protocols for up scalable, high quality isolation of kMSCs and precisely characterize kMSC function in comparison to other MSCs.• test kMSCs in several murine renal disease models, to study their effects on fibrosis and tissue repair.• discover mechanisms of kidney repair.• invest in developing the technology necessary for up scaled isolation and quality control.The STELLAR consortium combines Australian experts on kMSC isolation and characterisation with European experts on renal failure and compounds the state-of-the-art knowledge, facilities and experience needed to develop and validate this novel form of renal therapy. The inclusion of experienced SMEs, with great technical and scientific know-how about assay and protocol development, further strengthens the consortium and will ensure not only the inclusion of new technology, but also a quick translation from bench to clinical application.In conclusion, the STELLAR consortium is capable of developing and pre clinical validation of this new cellular therapy for CDK, based on a new understanding of stromal cells and fibroblast function, while also providing the technology required for rapid, large scale application of the therapy after clinical validation.
Project Terms:
scientific research